Baltimore, MDNCT04067336Now EnrollingIRB Ready

Acute Myeloid Leukemia Clinical Trial in Baltimore, MD

Access cutting-edge acute myeloid leukemia treatment through this clinical trial at a research site in Baltimore. Study-provided care at no cost to qualified participants.

Sponsored by Kura Oncology, Inc.

Quick Self-Assessment

See if you qualify for this Baltimore location

Preparing your pre-screening questions...

Expert Care in Baltimore

Access acute myeloid leukemia specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related acute myeloid leukemia treatment provided free

Apply for This Baltimore Location

Check if you qualify for this acute myeloid leukemia clinical trial in Baltimore, MD

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Baltimore

    Convenient for MD residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Baltimore site if eligible
  4. 4Begin participation

About This Acute Myeloid Leukemia Study in Baltimore

In this trial, ziftomenib, a menin-MLL(KMT2A) inhibitor, will be tested in patients for the first time. The trial includes a Main Study and four sub-studies. In the Main Study (including Phase 1a, Phase 1b, and Phase 2 portions), ziftomenib will be evaluated in patients with relapsed or refractory (R/R) acute myeloid leukemia (AML). The main study has completed enrollment. In Sub-studies 1 and 2, the effects of taking ziftomenib and other common drugs at the same time will be investigated in AM

Sponsor: Kura Oncology, Inc.

Who Can Participate

Inclusion Criteria

Patients with refractory or relapsed AML defined as the reappearance of ≥ 5% blasts in the bone marrow and who have also failed or are ineligible for any approved standard of care therapies, including HSCT. 1. Phase 1b:
Patients with a documented lysine\[K\]-specific methyltransferase 2-rearrangement (KMT2A-r), or
Patients with a documented nucleophosmin 1 mutation (NPM1-m) 2. Phase 2:
Patients with a documented nucleophosmin 1 mutation (NPM1-m) 3. Sub-studies:
Sub-studies 1 and 2: Patients with R/R AML with NPM1-m or other mutations associated with MEIS1 overexpression.
Sub-study 3: Patients with R/R Acute Lymphoblastic Leukemia (ALL) with KMT2A-r.
Sub-study 4: Patients with R/R AML with mutations associated with MEIS1 overexpression. 4. ≥ 18 years of age. 5. Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2, and a life expectancy of at least 2 months. 6. Adequate liver and kidney function according to pro

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Baltimore?

Yes, this clinical trial (NCT04067336) has an active research site in Baltimore, MD that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Acute Myeloid Leukemia Treatment Options in Baltimore, MD

If you're searching for acute myeloid leukemia treatment options in Baltimore, MD, this clinical trial (NCT04067336) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Baltimore research site is actively enrolling participants for this clinical trial. You'll receive care from experienced acute myeloid leukemia specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all acute myeloid leukemia clinical trials near you to find additional studies recruiting in your area.

More Leukemia Trials in Baltimore, MD

See all leukemia clinical trials recruiting in Baltimore — not just this study.

Browse Leukemia Trials in Baltimore →

Browse More Trials by Condition

Leukemia TrialsAcute Myeloid Leukemia TrialsHeart Attack TrialsMyocardial Infarction TrialsOsteogenesis Imperfecta TrialsAll Conditions →

Ready to Join in Baltimore?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Baltimore, MD